Xenon Pharmaceuticals Inc.

For the period ended Sep 30, 2025. Filed Nov 3, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 3, 2025

XENE$41.39+2.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Expressed in thousands of U.S. dollars except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Collaboration revenue (note 9)	$—	$—	$7,500	$—
Operating expenses:
Research and development	77,054	56,970	213,239	150,922
General and administrative	19,282	16,706	57,564	50,899
Total operating expenses	96,336	73,676	270,803	201,821
Loss from operations	(96,336)	(73,676)	(263,303)	(201,821)
Other income:
Interest income	6,206	10,329	21,488	32,521
Foreign exchange gain (loss)	(89)	237	1,644	414
Total other income	6,117	10,566	23,132	32,935
Loss before income taxes	(90,219)	(63,110)	(240,171)	(168,886)
Income tax recovery (expense)	(677)	320	(478)	241
Net loss	$(90,896)	$(62,790)	$(240,649)	$(168,645)
Other comprehensive income:
Unrealized gain on available-for-sale securities (note 5)	364	3,548	2,089	1,413
Comprehensive loss	$(90,532)	$(59,242)	$(238,560)	$(167,232)
Net loss per common share (note 10):
Basic and diluted	$(1.15)	$(0.81)	$(3.05)	$(2.17)
Weighted-average common shares outstanding (note 10):
Basic and diluted	79,247,976	77,926,205	78,962,975	77,730,644

-4-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.